Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

Area of Science:

• Nephrology
• Immunology
• Rheumatology

Background:

• Lupus nephritis is a severe complication of systemic lupus erythematosus.
• Standard treatments like intravenous cyclophosphamide carry significant side effects.
• There is a need for safer and effective alternative therapies.

Purpose of the Study:

• To evaluate the efficacy of monthly intravenous immunoglobulin (IVIg) in maintaining remission of proliferative lupus nephritis.
• To compare the efficacy of IVIg with standard intravenous cyclophosphamide (IVCYC) treatment.

Main Methods:

• A randomized trial involving 14 patients with proliferative lupus nephritis.
• Patients received either monthly IVIg or standard IVCYC for 18 months.
• Remission rates were assessed over the 18-month study period.

Main Results:

• Monthly IVIg maintained remission in patients with proliferative lupus nephritis over 18 months.
• The remission rates were comparable to those achieved with standard IVCYC treatment.
• No significant differences in efficacy were observed between the two treatment groups.

Conclusions:

• Pulsed intravenous immunoglobulin is a viable alternative therapy for maintaining remission in lupus nephritis.
• IVIg offers a potentially safer treatment option compared to IVCYC.
• Further research is warranted to confirm these findings in larger patient cohorts.